Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma

This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Dalia Ricci, Angela, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732236/
https://www.ncbi.nlm.nih.gov/pubmed/35993601
http://dx.doi.org/10.1093/oncolo/oyac168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732236/
https://www.ncbi.nlm.nih.gov/pubmed/35993601
http://dx.doi.org/10.1093/oncolo/oyac168

Ejemplares similares